**Publication year: 2022**

**Cochrane Hepato-Biliary Group (CHBG)**

1. **Publications on the Cochrane Database of Systematic Reviews (CDSR) in the Cochrane Library (CLib), including contributors**
2. **Registered and deregistered titles**
3. **Withdrawn protocols**

**Reviews**

|  |  |  |
| --- | --- | --- |
|  | **Reference** | **Contributors**  |
| **1.** | Liu B, Zhang Y, Chen H, Li W, Tsochatzis E. *The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma*. Cochrane Database of Systematic Reviews 2022, Issue 1. Art. No.: CD013345. DOI: 10.1002/14651858.CD013345.pub2. (Accessed 10 January 2022) | **Sign‐off editor**: Christian Gluud, Denmark**Contact editors**: Stefano Trastulli, Italy; Luit Penninga, Denmark**Managing Editor** (selected peer reviewers, provided editorial guidance to authors, edited the article): Dimitrinka Nikolova, Denmark**Peer reviewers**: Karl Heinz Weiss, Germany; Vanja Giljaca, UK**Methodological Editor**: Theresa Moore, UK**Methods Support Unit Lead and Statistical Editor**: Kerry Dwan, UKCochrane Abdomen and Endocrine **Network Editor**: Rachel Richardson, UK |
| **2.** | Nadarevic T, Colli A, Giljaca V, Fraquelli M, Casazza G, Manzotti C, Štimac D, Miletic D. *Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.* Cochrane Database of Systematic Reviews 2022, Issue 5. Art. No.: CD014798. DOI: 10.1002/14651858.CD014798.pub2. (Accessed 06 May 2022) | **CHBG Editorial teamSign‐off Editor** (final editorial decision): Christian Gluud, Co‐ordinating Editor CHBG, Denmark**Contact Editor** (provided editorial decision): Chavdar Pavlov, Russia**Managing Editor** (selected peer reviewers, provided editorial guidance to authors, edited the article): Dimitrinka Nikolova, Denmark**Information Specialist** (database searches): Sarah Louise Klingenberg, Denmark**Peer‐reviewer** (provided clinical and content review comments): Rita Golfieri, IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Italy.**Cochrane Diagnostic Test Accuracy Editorial TeamSign‐off Editor** (DTAR methods): Ingrid Arevalo‐Rodriguez, Clinical Biostatistics Unit, Spain, and Screening and Diagnostic Tests Methods Group, UK**Peer‐reviewers** (general methods): Keele University, UK; (statistical comments) Enzo Cerullo, University of Leicester, UK; (peer review of search strategies): Kate Misso, Information Retrieval Methods Group, UK.**Copy Editor** (copy editing and production): Anne Lawson, Copy Edit Support, Cochrane. |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

**Protocols**

|  |  |  |
| --- | --- | --- |
|  | **Reference** | **Contributors**  |
| **1.** | Tabei K, Win TZ, Kitashoji E, Brett-Major DM, Edwards T, Smith C, Mukadi P. *Antibiotic prophylaxis for leptospirosis.* Cochrane Database of Systematic Reviews 2022, Issue 2. Art. No.: CD014959. DOI: 10.1002/14651858.CD014959. (Accessed 25 February 2022) | **Peer Reviewers**: Ingrid Ting‐Ting Chen, USA; Htar Htar Aung, Malaysia**Contact Editor**: Joshua Feinberg, Denmark**Sign‐off Editor**: Christian Gluud, Denmark**Associate Editor, Evidence Production and Methods** Department, Cochrane: Rachel Richardson, UK |
| **2.** | Shiraiwa DK, Riera R, Kleinubing DR, Linhares MMoura. *Associating liver partition and portal vein ligation for staged hepatectomy procedure versus conventional two‐stage hepatectomy for colorectal liver metastasis.* Cochrane Database of Systematic Reviews 2022, Issue 3. Art. No.: CD014608. DOI: 10.1002/14651858.CD014608. (Accessed 8 March 2022) | **Peer reviewers:** Vishal G Shelat, Canada; Per Sandstöm, Sweden; Andreas A Schnitzbauer, Germany; Vishal G Shelat, USA; Alfred Kow Wei Chieh, Singapore; Stylianos Kykalos, Greece**Statistician**: Giovanni Casazza, Italy**Contact Editor**: Brian Davidson, UK**Sign‐off Editor**: Luit Penninga, Denmark**Associate Editor, Evidence Production and Methods Department, Cochrane:** Rachel Richardson, UK |
| **3.** | Htet NH, Naing C, Vongpunsawad S, Win TT, Poovorawan Y. *Thymosin‐ɑ1 for people with chronic hepatitis B.* Cochrane Database of Systematic Reviews 2022, Issue 3. Art. No.: CD014610. DOI: 10.1002/14651858.CD014610. (Accessed 17 March 2022)  | **Sign‐off Editor** (final editorial decision): Christian Gluud, Co‐ordinating Editor, Denmark.**Contact Editor** (provided editorial decision): Daniele Prati, Editor, Italy.**Managing Editor** (selected peer reviewers, provided editorial guidance to authors, edited the protocol): Dimitrinka Nikolova, Denmark.**Peer‐reviewers** (provided clinical and content review comments): Mona H Ismail, Saudi Arabia; Kerry Dwan (peer reviewer of review methods), Methods Support Unit, Editorial and Methods Department, UK.**Associate Editor**: Rachel Richardson, Evidence Production and Methods Department, Cochrane, UK.**Copy Editor** (copy editing and production): Anne Lawson, Cochrane Copy Edit Support, UK. |
| **4.** | Mukadi P, Tabei K, Edwards T, Brett-Major DM, Smith C, Kitashoji E, Win TZ. *Antibiotics for treatment of leptospirosis.* Cochrane Database of Systematic Reviews 2022, Issue 5. Art. No.: CD014960. DOI: 10.1002/14651858.CD014960. (Accessed 28 May 2022) | **Sign-off Editor** (final editorial decision): Christian Gluud, Co- ordinating Editor Cochrane Hepato-Biliary Group, Denmark. **Contact Editor** (provided editorial decision): Joshua Feinberg, Denmark. **Statistical Editor** (commented on statistics): Giovanni Casazza, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Italy. **Managing Editor** (selected peer reviewers, provided editorial guidance to authors, edited the article): Dimitrinka Nikolova, Denmark. **Information Specialist** (database searches): Sarah Louise Klingenberg, Denmark.**Peer-reviewers** (provided clinical and content review comments): Christopher Parry, Liverpool School of Tropical Medicine, UK; Marta Ferreira Maia, KEMRI-Wellcome Trust Research Programme, Kenya; Cho Niang, James Cook University, Queensland, Australia; (Information Specialist review): Robin M Featherstone, Editorial & Methods Department, Cochrane Executive, London, UK. **Associate Editor:** Rachel Richardson, Evidence Production and Methods Department, Cochrane, UK.**Copy Editor** (copy editing and production): Anne Lawson, Copy Edit Support, Cochrane, UK. |
| **5.** | Wen H, Deng H, Yang L, Li L, Lin J, Zheng P, Ji G. Vitamin E for people with non‐alcoholic fatty liver disease. Cochrane Database of Systematic Reviews 2022, Issue 5. Art. No.: CD015033. DOI: 10.1002/14651858.CD015033. (Accessed 31 May 2022) | **Sign‐off Editor** (final editorial decision): Christian Gluud, Co‐ordinating Editor, Denmark.**Contact Editor** (provided editorial decision): Goran Bjelakovic, Editor, Serbia.**Managing Editor** (selected peer reviewers, provided editorial guidance to authors, edited the protocol): Dimitrinka Nikolova, Denmark.**Peer‐reviewers** (provided clinical and content review comments): Janus Christian Jakobsen, Denmark; Marija Bjelakovic, Serbia; (peer review of review methods) Ghid Kanaan, USA.**Associate Editor:** Rachel Richardson, Evidence Production and Methods Department, Cochrane, UK.**Copy Editor** (copy editing and production): Anne Lawson, Copy Edit Support, Cochrane. |
| 6. | Corticosteroids for treatment of leptospirosis. Kitashoji E, Tabei K, Smith C, Mukadi P, Win TZ, Edwards T, Lee N. Cochrane Database of Systematic Reviews 2022, Issue 7. Art. | **Sign-off Editor** (final editorial decision): Goran Poropat, Editor CHBG, Croatia.**Contact Editor** (provided editorial decision): Lise Lotte Gluud, Editor CHBG, Denmark.**Statistical Editor:** Giovanni Casazza, Italy.**Managing Editor** (selected peer reviewers, provided editorial guidance to authors, edited the article): Dimitrinka Nikolova, Denmark. **Information Specialist** (database searches): Sarah Louise Klingenberg, Denmark.**External or internal peer-reviewers** (provided clinical and content review comments): Hasifa Bukirwa, African Field Epidemiology Network, Kampala, Uganda; Joshua Feinberg, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark.**Information Specialist for review**: Robin M Featherstone, Editorial & Methods Department, Cochrane Executive, London, UK.**Associate Editor**: Rachel Richardson, UK, Evidence Production and Methods Department, Cochrane, UK.**Copy Editor** (copy editing and production): Anne Lawson, Copy Edit Support, Central Production Service, Cochrane. |

II. Registered titles

|  |  |  |
| --- | --- | --- |
|  | **Reference** | **Contributors**  |
| **1.** | Entecavir for chronic hepatitis B. Wu J, Xie S, Ma Y, He X, Dong X, Shi Q, Guo Q, Wang Q, Li M, Yao N. Registered 31.03.2022 |  |
| **2.** | Liver and spleen stiffness for the diagnosis of oesophageal varices in people with chronic liver disease. Fraquelli M, Vranic L, Nadarevic T, Štimac D, Manzotti C, Fichera A, Casazza G, Colli A. Registered 20.04.2022 |  |
| **3.**  | Silymarin for treatment of people with nonalcoholic fatty liver disease. Qi X, Wang C. Registered 29.04.2022 |  |
| 4. | Tenofovir for chronic hepatitis B. Li H, Yang M, Mina M, Li Z, Li M, Li H, Yao L, Zhong L, Yang K. Registered 20.05.2022 |  |
| **5.** | Tenofovir versus entecavir for chronic hepatitis B. Li M, Yao L, Qin Y, Li Y, Mina M, Yang M, Guo KG, Wang Q, Li H, Li X, Yang K. Registered 18.07.2022 |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

Tenofovir versus entecavir for chronic hepatitis B